Health ArticleEducational review — not personal medical advice

Understanding Lymph Node Management in Breast Cancer: What Every Patient Should Know

20 min

Table of Contents

Key Points

  • The armpit lymph nodes receive about 85 percent of breast lymphatic drainage, making them the first and most common site of spread.
  • Physical exam alone misses many positive lymph nodes; in the NSABP B-32 trial, 26 percent of clinically negative patients had node-positive disease.
  • Trials Z0011, AMAROS, and OTOASOR show that patients with one or two positive sentinel nodes can safely skip ALND and use radiation instead, with similar survival.
  • Targeted axillary dissection, which removes a marked positive node, reduced the sentinel node biopsy false negative rate from 12.6 percent to 6.8 percent in the Z1071 trial.
  • ALND causes more lymphedema than axillary radiation, so combining both is generally avoided unless the risk of recurrence is very high.

Introduction: Why Lymph Nodes Matter in Breast Cancer

When breast cancer spreads beyond the breast itself, it most often travels first through the lymphatic system—a network of vessels and small, bean-shaped organs called lymph nodes that help filter fluid and fight infection. The lymphatic drainage areas of the breast include the axillary (armpit), internal mammary (along the breastbone), and supraclavicular (above the collarbone) lymph node groups. These are the nodes most likely to contain cancer cells in patients with metastatic breast cancer.

This article reviews the risk of breast cancer spreading to these regional lymph nodes, how doctors assess the armpit before surgery, and the current indications for axillary lymph node dissection versus axillary radiation. Understanding these concepts can help patients participate more confidently in decisions about their care.

The Regional Lymph Nodes: Where Breast Cancer Spreads First

The axillary lymph nodes receive the majority of lymphatic drainage from all quadrants of the breast—approximately 85 percent. The remaining drainage goes to the internal mammary, infraclavicular (below the collarbone), and supraclavicular lymph nodes.

Several factors influence whether cancer has reached these nodes, including tumor size, tumor location, and specific microscopic features such as grade, lymphatic invasion, and hormone receptor status.

Axillary Lymph Nodes (Under the Armpit)

The likelihood that cancer has spread to the axillary lymph nodes (ALNs) depends on several tumor characteristics:

  • Tumor size: In general, larger primary tumors are associated with a higher likelihood of ALN involvement, although this can vary by tumor subtype. In a series of 6,800 women diagnosed with invasive breast cancer after screening mammography, the incidence rate of ALN involvement increased steadily with tumor size.
  • Small tumors can still spread: ALN metastases are relatively common even with invasive breast cancers measuring ≤1 cm. In a report of 919 women who underwent ALN dissection, metastases were detected in 16 percent of those with T1a tumors (tumor size 0.1 to 0.5 cm) and 19 percent of those with T1b tumors (tumor size 0.5 to 1.0 cm).
  • Tumor location: Tumors in the lateral (outer) portion of the breast are more likely to spread to the armpit nodes than tumors in the medial (inner) portion. In a study of 1,671 early-stage breast cancers, the odds ratio of a lateral tumor having axillary metastasis was 1.33 (95% CI 0.95–1.87) compared with a medial tumor. The most likely explanation is that some medial tumors drain preferentially to the internal mammary nodes instead.
  • Histologic grade: Grade 1 tumors (slow-growing, well-differentiated) have a significantly lower rate of axillary metastases than grade 2 or 3 tumors. Using data from the Surveillance, Epidemiology, and End Results (SEER) database, the incidence of ALN involvement in patients with grade 1 versus grade 3 tumors of similar size was 3.4 percent versus 21 percent, respectively.
  • Low-risk tumor types: Tumors associated with a less than 5 percent risk of axillary metastases include those with a single focus of microinvasion, <5 mm grade 1 tumors without lymphatic invasion, and pure mucinous or pure tubular carcinomas smaller than 1 cm.
  • Tumor subtype: After adjusting for size, some subtypes (e.g., HER2-positive and triple-negative) have higher node positivity rates than others (e.g., luminal/hormone-receptor positive).
  • Detection method: Across all size categories, patients whose invasive tumors are detected by screening mammography are more likely to have pathologically negative lymph nodes than those whose tumors are found clinically.

Internal Mammary Lymph Nodes (Along the Breastbone)

The internal mammary nodes (IMNs) receive drainage from all quadrants of the breast, but medial tumors have a significantly higher rate of IMN metastases. Although the IMN chain extends from the fifth intercostal space to the retroclavicular region, nodes in the upper three interspaces are most likely to contain metastases.

Isolated IMN metastases are infrequent; more often, the axillary nodes are involved as well. In a report of over 7,000 cases in which both IMNs and ALNs were examined, IMN metastases were detected in 22 percent of patients, but fewer than 5 percent of the node-positive patients had IMN-only disease. Isolated IMN involvement was more frequent for medial than lateral tumors—7.6 percent versus 2.9 percent.

Regarding imaging, there are no convincing data that routine imaging of the IMNs is needed in clinically node-negative patients. They may be visualized incidentally during staging PET or chest CT scans, and the results can change the patient's nodal stage and potentially impact surgical and radiation treatment plans.

Management of the IMNs remains somewhat controversial:

  • Sentinel lymph node biopsy: Dissection of the IMNs during SLNB is considered investigational. Using standard technique, IMNs are only visualized in about 20 percent of patients during SLNB. An IMN is rarely positive if an axillary sentinel node is negative. Since the IMN status rarely changes management, very few surgeons perform SLNB of the IMN or attempt to identify these nodes preoperatively with lymphoscintigraphy. Potential complications of IMN biopsy include pleural effusion (fluid around the lung) and injury to the internal mammary artery.
  • Radical dissection: Following four early (1960s) randomized trials showing no survival benefit from extended mastectomy (which included IMN dissection) compared with radical or modified radical mastectomy, routine dissection of the IMNs was abandoned. In addition, the widespread use of adjuvant systemic therapy (chemotherapy, hormonal therapy, or targeted therapy after surgery) has diminished the importance of the IMNs in clinical care.
  • Radiation therapy: For women receiving adjuvant regional radiation therapy—either after breast-conserving surgery or with postmastectomy radiation—radiation of the IMNs is generally included. However, an individualized approach is necessary, taking into account the patient's risk of IMN involvement, her anatomy, and the ability to protect critical structures like the heart from the radiation field.

Supraclavicular Lymph Nodes (Above the Collarbone)

Supraclavicular nodal metastases are usually associated with extensive axillary node involvement and are rare without it. In a series of 274 women undergoing routine supraclavicular dissection, supraclavicular metastases were found in 18 percent of those with axillary metastases but only 0.7 percent of those without.

These metastases represent locally advanced disease. Nonetheless, curative treatment is possible with aggressive multimodality treatment—typically consisting of neoadjuvant systemic therapy (treatment given before surgery), surgery, possible additional adjuvant systemic therapy, and radiation.

How Doctors Evaluate the Axilla

Before deciding on treatment, the armpit area can be evaluated using three complementary tools: physical examination, axillary ultrasound, and/or percutaneous needle biopsy (either core needle biopsy [CNB] or fine needle aspiration [FNA]). The optimal pathway depends on the tumor size and its pathologic features, including receptor status, because these factors influence whether neoadjuvant systemic treatment will be recommended.

Physical Examination

All patients undergo a physical examination of the axilla, but this exam is neither sensitive nor reliable on its own. Metastatic lymph nodes are often not palpable, and benign reactive lymph nodes may be mistaken for metastases. The positive predictive value of clinical palpation—the likelihood of finding axillary metastases when the exam is suspicious—ranges from 61 to 84 percent. The negative predictive value—the likelihood of no metastases when the exam is normal—is only 50 to 60 percent.

In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-32 sentinel node trial, among patients with clinically negative axillary nodes, the node-positive rate was 26 percent. This means that about one in four patients with a normal-feeling armpit still had cancer in their lymph nodes.

Axillary Ultrasound

Axillary ultrasound is an effective screening method for detecting nodal metastasis in patients with invasive breast cancer. However, its accuracy is operator-dependent, so results can vary between centers.

The use of axillary ultrasound in newly diagnosed patients varies. Some experts routinely perform it in all patients with invasive breast cancer; others reserve it for patients with palpable nodes or those planning neoadjuvant chemotherapy.

For patients not planning neoadjuvant chemotherapy, the benefit of preoperative axillary ultrasound is debated:

  • Proponents argue that ultrasound staging can identify patients with a high axillary disease burden—defined as ≥3 metastatic nodes, extranodal extension, or level III nodes—who may go directly to ALND. In a retrospective study of patients with only one metastatic node on preoperative ultrasound who met the Z0011 criteria, ultrasound had a sensitivity and negative predictive value of 92 percent and a false negative rate of 8 percent—performance comparable to that of SLNB.
  • Opponents argue that early breast cancer patients are unlikely to have many involved nodes, that ultrasound cannot reliably distinguish between one or two positive nodes versus three or more, and that it does not add sufficient information beyond SLNB to change management.

Three ongoing trials—the SOUND trial (NCT02167490), the INSEMA trial, and the BOOG 2013-08 trial—are evaluating whether patients with a negative axillary ultrasound even need additional axillary surgery at all. Their results may further de-escalate axillary surgery for breast cancer.

For patients planning neoadjuvant chemotherapy, ultrasound offers a clear benefit: it permits targeted axillary dissection by identifying, guiding biopsy of, and marking any positive nodes with a clip or tattoo before chemotherapy begins. In the Z1071 trial, targeted axillary dissection reduced the false negative rate of SLNB from 12.6 percent to 6.8 percent in patients with positive axillary nodes undergoing neoadjuvant treatment.

Percutaneous Needle Biopsy

Abnormal lymph nodes found on axillary ultrasound should undergo needle biopsy for pathologic analysis. Both core needle biopsy (CNB) and fine needle aspiration (FNA) can be performed percutaneously under ultrasound guidance. However, until more data become available, a needle biopsy of an abnormal node does not replace surgical evaluation—SLNB is still required in most patients with breast cancer.

Managing the Axilla: Treatment Options

The decision to give neoadjuvant chemotherapy, endocrine therapy, or immunotherapy depends on the hormone receptor and HER2 status of the cancer and its stage. The overall approach to the axilla depends largely on whether the patient received neoadjuvant treatment.

The Benefit of Axillary Treatment

Axillary treatment improves regional disease control—that is, it reduces the chance that cancer will come back in the armpit area. However, with modern systemic treatments, there is no clear evidence that treating the axilla improves overall survival.

This was powerfully demonstrated in the landmark NSABP B-04 trial, conducted from 1971 to 1974. In that study, clinically node-negative patients were randomly assigned to one of three treatments:

  1. Total mastectomy with axillary lymph node dissection (ALND)
  2. Total mastectomy with regional radiation therapy (RT)
  3. Total mastectomy alone, with delayed ALND at the time of any recurrence

Although the 10-year survival was similar across all three groups, the axillary failure rate was significantly higher in women treated with mastectomy alone (18 percent) compared with those receiving regional RT or initial ALND (3.1 percent and 1.4 percent, respectively). The authors note that the true failure rate in the delayed-ALND group was probably even higher than 18 percent, because inoperable recurrences and recurrences that happened alongside distant metastases were excluded from the calculation.

It is important to recognize the context of the B-04 era: mammographic screening was neither widespread nor as sophisticated, adjuvant systemic therapy was less refined, and the average tumor size was generally larger than what is found today. Since the likelihood of subclinical axillary metastases increases with tumor size, experts anticipate that axillary failure rates without dissection or radiation today would be significantly lower—especially with modern systemic regimens. Indeed, in the more recent Z0011 trial, the axillary relapse rate was just 0.5 percent with ALND and 1 percent with SLNB alone.

Comparing Treatment Modalities

There are two main modalities of axillary treatment: surgery (sentinel lymph node biopsy, targeted axillary dissection, or axillary lymph node dissection) and radiation (regional radiotherapy). Given randomized trial data showing that many women with limited or no sentinel node involvement can safely omit ALND and be treated with radiation alone, this has become the standard approach for women who meet the "Z0011 criteria."

Both surgery and radiation to the armpit increase the risk of long-term swelling of the arm on the same side (ipsilateral lymphedema), so using both together is often avoided except in very high-risk situations.

  • Sentinel lymph node biopsy (SLNB): In patients with clinically node-negative early breast cancer, SLNB identifies those with limited or no axillary node involvement, allowing them to avoid more extensive surgery. The decision to proceed with ALND is based on the SLNB results, primary tumor size, and other factors.
  • Targeted axillary dissection (TAD): TAD is a newer staging technique that removes any biopsy-proven positive axillary nodes (previously marked with a clip or tattoo before neoadjuvant chemotherapy) in addition to performing SLNB. TAD targets the removal of positive nodes while minimizing the morbidity of a full dissection. In a meta-analysis of over 3,000 patients, the pooled success rate of identifying and retrieving a marked node was 90.0 percent (95% CI 85.1–95.1). Compared with ALND across 13 studies, TAD was associated with a false negative rate of 5.18 percent (95% CI 3.41–7.54).
  • Axillary lymph node dissection (ALND): ALND is the traditional and most complete surgical removal of lymph nodes from the armpit. It provides excellent disease control and important prognostic information, and it guides treatment selection. However, the anatomic disruption it causes can lead to lymphedema, nerve injury, and shoulder dysfunction, all of which compromise function and quality of life. ALND was once a routine part of breast cancer care, but SLNB is now the standard initial approach for women with early breast cancer who meet the Z0011 criteria.
  • Regional radiotherapy: Standard whole breast radiation after lumpectomy—or postmastectomy radiation—includes two tangential radiation fields to the breast or chest wall, which generally covers the lower portion of the axillary nodes. Full regional RT uses an additional third (and sometimes fourth) field to treat the supraclavicular, infraclavicular, and upper axillary nodes.

Several randomized trials have directly compared outcomes in women treated with ALND versus regional RT for early-stage breast cancer. All have shown low rates of axillary failure after either approach and similar long-term survival—allowing many women to avoid ALND by incorporating regional RT instead.

The AMAROS Trial

Reported in 2014, the After Mapping of the Axilla: Radiotherapy or Surgery (AMAROS) trial was a large multi-institutional study that included 4,806 patients with T1 or T2 unifocal invasive breast cancer and no palpable axillary lymphadenopathy. Among the 1,425 patients found to have positive sentinel nodes on SLNB:

  • 744 were randomly assigned to receive ALND
  • 681 were randomly assigned to receive axillary radiotherapy

Ninety-five percent of patients in both groups had one or two positive sentinel nodes. At five years, the axillary recurrence rate was 0.43 percent (95% CI 0–0.92) in the ALND group and 1.19 percent (95% CI 0.31–2.08) in the radiation group. There were no statistically significant differences in survival between the treatment groups. However, lymphedema was reported significantly more often after ALND than after axillary radiation at one, three, and five years.

At 10-year follow-up, the axillary recurrence rate remained low and comparable: 0.93 percent in the ALND group (7 of 744 patients) versus 1.82 percent in the radiation group (11 of 681 patients). Distant metastasis-free survival and overall survival were similar. Interestingly, the trial found that more second primary cancers developed in the patients treated with axillary radiotherapy (11.0 percent versus 7.7 percent, p = 0.035); some of these were cancers in the opposite breast, and it remains unclear how much of this increase was due to radiation versus chance alone.

The OTOASOR Trial

In the OTOASOR trial, 474 patients with tumors ≤3 cm, clinically node-negative disease, and a positive sentinel node biopsy were randomly assigned to completion ALND versus axillary radiation. There was no statistically significant difference between the two groups in axillary recurrence or overall survival—either at 40 months (axillary recurrence 0.82 percent for ALND versus 1.3 percent for radiation) or at 97 months (axillary recurrence 2 percent versus 1.7 percent; overall survival 77.9 percent versus 84.8 percent; disease-free survival 72.1 percent versus 77.4 percent).

Patients Who Do Not Receive Neoadjuvant Therapy

Most patients without known axillary metastases before surgery undergo SLNB at the time of their primary breast surgery. SLNB reliably distinguishes between patients who require ALND and those who do not. For patients who are found to have no axillary metastasis on preoperative evaluation, SLNB is the standard method of axillary staging.

The choice of whether to proceed with ALND or regional nodal irradiation—or both—after a positive SLNB depends on the extent of node involvement, the characteristics of the primary tumor, and the patient's overall treatment plan, guided by the randomized evidence summarized above.

Clinical Implications for Patients

For patients facing a new breast cancer diagnosis, these findings translate into several important practical messages:

  • Not every positive lymph node requires full removal. The Z0011, AMAROS, and OTOASOR trials collectively demonstrate that women with one or two positive sentinel nodes can safely skip ALND and be treated with radiation alone (or in some cases, with no further axillary treatment), with very low rates of recurrence and no loss of survival.
  • Lymphedema risk is lower with less surgery. Since both surgery and radiation can cause arm swelling, combining them is avoided whenever possible. Avoiding ALND where safe helps preserve quality of life.
  • Targeted axillary dissection is a promising middle ground. For patients receiving chemotherapy before surgery, marking the positive node beforehand allows surgeons to remove it selectively—reducing false negative rates from 12.6 percent to 6.8 percent.
  • The internal mammary nodes rarely need separate treatment. Because isolated IMN involvement is uncommon (fewer than 5 percent of node-positive patients), and because systemic therapy is so effective, routine biopsy or dissection of these nodes has been abandoned.
  • Supraclavicular spread is not hopeless. Even when cancer reaches nodes above the collarbone, aggressive treatment with systemic therapy, surgery, and radiation can still be curative.

Limitations of the Current Evidence

It is important to understand what this body of evidence cannot tell us. The B-04 trial reflects an era of larger tumors, less effective systemic therapy, and less sophisticated screening; its 18 percent axillary failure rate with mastectomy alone is likely far higher than what would be seen today. The AMAROS trial's finding of more second primary cancers in the radiation group is incompletely understood—it is unclear how much reflects the radiation itself versus chance. Additionally, ultrasound accuracy is operator-dependent, meaning its usefulness varies from center to center. Several ongoing trials (SOUND, INSEMA, and BOOG 2013-08) are still investigating whether some patients with a negative ultrasound can skip axillary surgery altogether, and their results will further refine these recommendations.

Recommendations for Patients

Based on the current evidence, here is practical guidance for women navigating breast cancer treatment decisions:

  1. Ask your surgeon about your specific risk factors. Tumor size, grade, location, and receptor status all influence the likelihood of lymph node involvement—and therefore the appropriate surgical plan.
  2. Understand that a negative physical exam is not conclusive. Because clinical palpation misses many positive nodes (the node-positive rate in clinically negative patients was 26 percent in NSABP B-32), imaging and surgical staging play critical roles.
  3. Discuss whether axillary ultrasound will be performed. If you are planning neoadjuvant chemotherapy, ultrasound-guided biopsy with marking of any positive node is particularly valuable, as it enables targeted axillary dissection later.
  4. If your sentinel node is positive with limited involvement, ask whether ALND can be avoided. The evidence strongly supports omitting ALND in many patients with one or two positive sentinel nodes, especially those meeting Z0011 criteria.
  5. Weigh the risks of lymphedema carefully. If both surgery and radiation to the armpit are being proposed, ask your care team about the specific reasons and risks, since combining them is generally avoided.
  6. Stay informed about clinical trials. The SOUND, INSEMA, and BOOG 2013-08 trials are testing whether even SLNB can be safely omitted in some patients with negative ultrasounds. Ask your oncologist whether any ongoing studies might be relevant to your situation.
  7. Treat the whole picture. Axillary treatment improves regional control, but survival is driven predominantly by systemic treatment. Your chemotherapy, endocrine therapy, or HER2-targeted therapy is at least as important as the lymph node surgery in determining your long-term outcome.

Frequently Asked Questions

What are the lymph nodes most likely to be affected when breast cancer spreads?

Breast cancer usually spreads first through the lymphatic system to three nearby lymph node groups: under the armpit (axillary), along the breastbone (internal mammary), and above the collarbone (supraclavicular). The armpit nodes receive most of the breast's drainage, about 85 percent, so they are the most common site of early spread.

How do doctors check whether breast cancer has spread to the armpit lymph nodes?

Doctors use three tools: a physical exam, an axillary ultrasound, and a needle biopsy of any suspicious node. Physical exam alone is not reliable, missing many positive nodes. Ultrasound can spot abnormal nodes, and a needle biopsy confirms cancer. However, surgery with sentinel lymph node biopsy is still required for most patients to stage the armpit accurately.

What is sentinel lymph node biopsy (SLNB) and why is it done?

Sentinel lymph node biopsy is a surgery that removes only the first few lymph nodes that receive drainage from the breast, called sentinel nodes. It identifies whether cancer has spread and whether more extensive surgery is needed. For patients with early breast cancer and no clinically positive nodes, SLNB is the standard method of staging the armpit, helping many avoid full dissection.

Can I avoid axillary lymph node dissection if my sentinel node is positive?

In many cases, yes. Landmark trials like Z0011, AMAROS, and OTOASOR showed that women with one or two positive sentinel nodes can safely skip full axillary dissection and instead receive radiation alone, without harming survival. Your surgeon will consider your tumor size, extent of node involvement, and overall treatment plan to decide if ALND can be avoided.

What is targeted axillary dissection (TAD) and who might need it?

Targeted axillary dissection combines sentinel node biopsy with removal of any biopsy-proven positive lymph node that was marked with a clip or tattoo before chemotherapy. It is used for patients receiving neoadjuvant treatment. In a meta-analysis, TAD successfully retrieved the marked node 90 percent of the time, and it cut the false negative rate of sentinel biopsy from 12.6 percent to 6.8 percent.

What are the risks of axillary lymph node dissection?

Axillary lymph node dissection can cause lymphedema, nerve injury, and shoulder dysfunction, affecting quality of life. In trials, lymphedema was significantly more common after ALND than after axillary radiation. Because both surgery and radiation can cause arm swelling, doctors usually avoid using both together unless the risk of recurrence is very high, to preserve arm function.

Why are internal mammary and supraclavicular lymph nodes rarely treated separately?

Internal mammary node spread is uncommon—fewer than 5 percent of node-positive patients have it alone—and systemic therapy is very effective, so routine biopsy or dissection of these nodes has been abandoned. Supraclavicular spread is rare without extensive axillary involvement and is treated with aggressive combination therapy, including systemic treatment, surgery, and radiation, which can still be curative.

Source Information

Original article title: Overview of management of the regional lymph nodes in breast cancer - UpToDate

Authors: Seth P Harlow, MD; Donald L Weaver, MD

Section Editors: Anees B Chagpar, MD, MSc, MA, MPH, MBA, FACS, FRCS(C); Daniel F Hayes, MD; David E Wazer, MD

Deputy Editors: Wenliang Chen, MD, PhD; Sadhna R Vora, MD

Publication details: Literature review current through November 2022; topic last updated August 31, 2022.

Note: This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from your oncology care team.

Refine su plan de tratamiento con un panel de médicos especialistas que se ajusten exactamente a su caso.

Refine su plan de tratamiento con un panel de médicos especialistas que se ajusten exactamente a su caso.

Can we help?

Encuentre cirujanos o especialistas médicos perfectos para realizar su tratamiento.

Can we help?
Encuentre cirujanos o especialistas médicos perfectos para realizar su tratamiento.